Importance of potentially inappropriate medications, number of chronic conditions and medications for the risk of hospitalisation in elderly in Sweden: a case–control study

Kristine Thorell 1, 2, Patrik Midlöv 1, Johan Fastbom, Anders Halling

ABSTRACT

Objectives This study aimed to investigate the importance of potentially inappropriate medications, number of medications and chronic conditions for the risk of hospitalisation among an elderly population.

Design This is a case–control study.

Setting Population-based study in 2013 of all individuals aged 75 years and older (17,203) in the county of Blekinge in the southeast of Sweden.

Participants A total of 2,941 individuals were included who had at least one hospitalisation to a medical, geriatric and palliative, or orthopaedic ward during 2013. From this total, 81 were excluded because of incomplete data or absence of controls. In total, 5,720 patients were included and formed 2,860 risk sets matched on age and gender.

Primary and secondary outcome measures Conditional logistic regression was used to analyse the odds for hospitalisation according to use of potentially inappropriate medication (PIM), number of chronic conditions and medicines using univariate and multivariate models. PIM was defined as long-acting benzodiazepines, tramadol, propiomazine and medicines with anticholinergic effect.

Results The univariate analysis for use of PIM showed a significant association with hospitalisation (OR 1.54, 95% CI 1.30 to 1.83). For the number of chronic conditions, the OR was increased and was significant from two or more chronic conditions, and for the number of medicines from the use of five or more medicines, in the univariate analysis. Use of PIM has no association with hospitalisation in the full model. The number of chronic conditions and medicines in the full models continued to have strong associations for hospitalisation, from five to seven chronic conditions (OR 1.86, 95% CI 1.49 to 2.33) and use of five to nine medicines (OR 1.46, 95% CI 1.21 to 1.77) at the same time.

Conclusion The number of chronic conditions and medications are important for the odds of hospitalisation, while the use of PIM, according to the definition used in this study, was no significant in the full model.

INTRODUCTION

The number of elderly people is rapidly increasing in the world. Better living conditions, advances in medical practice and drug development have all contributed to increased life expectancy. Estimations from demographic data indicates that 22% of the global population will be older than 65 by 2050. 1

With an ageing population, the use of medicines is increasing. Higher prevalence of multimorbidity as a result of longer life expectancy, advances in drug development and an increased specialisation of the medical profession are some explanations for this increase. 2 Multimorbidity, the coexistence of two or more chronic conditions at the same time in one person, is increasing with age and is one of the great challenges facing healthcare systems in the near future. It is associated with reduced quality of life, higher mortality, polypharmacy and high treatment burden. 3, 4 The development of new treatment opportunities,

To cite: Thorell K, Midlöv P, Fastbom J, et al. Importance of potentially inappropriate medications, number of chronic conditions and medications for the risk of hospitalisation in elderly in Sweden: a case–control study. BMJ Open 2019;9:e029477. doi:10.1136/bmjopen-2019-029477
both surgical and medical, has led to more complex treatment regimes. Polypharmacy is mostly defined as the use of five or more prescribed drugs at the same time. With polypharmacy, the risk of drug–drug interactions increases, and thereby the risk for adverse drug reaction (ADRs) and drug-related problems (DRPs) in elderly increases. The more complex the drug treatment, the more challenging it becomes to evaluate the risk–benefit ratio for treatments in elderly patients due to a lack of evidence. The knowledge about interactions are between medicines A and B, and there is very little existing knowledge about how medicine C interacts.4

Age-related physiological changes, higher proportion of fat in relation to body water or decreased renal function alter the pharmacokinetics and pharmacodynamics properties of medicines. Therefore, elderly people are more sensitive to certain medications and their effects, for example, drugs that are lipophilic or have a high renal clearance. Some drug treatments can therefore be potentially inappropriate in the elderly that are appropriate for younger or middle-aged patients.1 5

The term potentially inappropriate medication (PIM) is commonly used for these medications and is generally defined as medications that have side effects, that when used by older patients, outweigh the clinical benefits of the drug. Particularly when there are safer or more effective alternatives.6 The use of PIM in the elderly is associated with increased risk of ADRs. A majority of ADRs are type A reactions, which means that they originate from the pharmacological properties of the medication and are therefore predictable and preventable to a certain level.7–11 Many studies have analysed the risk of ADRs and DRPs in an elderly population and found that risk factors such as polypharmacy and use of PIM increase the risk.1 7–12 Polypharmacy is mostly defined as the use of five or more prescribed drugs at the same time and increases the risk of DRPs due to increased complexity of the medication treatment.4

ADRs can cause unplanned hospitalisations in elderly people, unnecessary suffering for patients and lead to larger costs for the healthcare system. It is estimated that about 10%–30% of all unplanned admissions for all ages are drug related and that the risk increases with age.7 8 12

The cause of a drug-related hospitalisation is multifaceted and complex. There are several steps in the prescribing process where, for different reasons, it can go wrong and cause an ADR in a patient. Some of the most common causes are communication problems between the prescriber and the patient, knowledge gaps about medications and/or patient medical history.10

To reduce the risk of ADR in the elderly caused by PIM, different recommendations have been developed regarding PIM and how to handle them clinically. Some of the most used recommendations and definitions of PIM are Beers criteria and the STOPP (Screening Tool of Older Persons’ potentially inappropriate Prescriptions) criteria.13 14 Sweden, among other countries, has made national recommendations to take country-specifics into consideration regarding the definition of PIM. In the Swedish National Board of Health and Welfare’s report ‘Quality indicators for good drug therapy in elderly’, the Swedish recommendations are specified. The indicators cover a range of different quality indicators for drug treatment in elderly. Some examples of indicators are medications not to use, inappropriate dosage and polypharmacy in the elderly. The indicator ‘Medicines that should be avoided unless there are special reasons’ is mostly defined as PIM in different quality criteria to evaluate medication use in elderly in Sweden.6

A large focus in recent years in Sweden has been on decreasing the use of PIM in order to prevent ADRs and DRP. Many county councils have different prescribing indicators to reduce the prescribing and use of different PIM. PIMs have been used as a proxy for decreasing drug-related morbidity and drug-caused hospitalisations in elderly. The aim of this study was to analyse the use of PIM, number of chronic conditions and number of medications as useable risk factors concerning hospitalisation. We analysed the association between use of PIM, number of chronic conditions and number of medications for unplanned hospitalisation in elderly patients.

**METHODS**

**Study design**

This study was a case–control study to analyse the use of PIM, number of chronic conditions and number of medications, and their association with unplanned hospitalisations in patients aged 75 years or older in Blekinge County, Sweden. The study was based on register data from both primary and secondary care in Blekinge County Council.

**Setting**

Blekinge is located in the south eastern corner of Sweden. It is one of the smallest counties in Sweden with only 152 315 inhabitants in 2013. We included individuals aged 75 or older that were registered to a primary care centre in Blekinge during 2013. In Sweden, almost all inhabitants are registered to a primary care centre. All primary care is funded by the county council through a specific county council tax. Both public (operated by the county council) and private care centres were included in the study. Nine (41%) of the primary care centres in Blekinge 2013 were private.

**Study population**

We included the first hospitalisation during 2013 to a medical, geriatric and palliative, or an orthopaedic ward for individuals 75 years and older in Blekinge County. Each case was matched to a control 1:1 in the population by age (birth year) and gender. Each matched case and control formed a risk set. The date of the first unplanned hospitalisation for each case was set to be the index date for each risk set.

**Potential inappropriate medication**

PIM was identified according to the Swedish National Board of Health and Welfare’s report ‘Quality indicators
for good drug therapy in elderly. The purpose of the indicators is to facilitate the follow-up of medical treatment. We used the indicator 1.1, ‘Medicines that should be avoided unless there are special reasons’. As the name states, it is medicines that should be avoided in patients, 75 years and older, unless there are special reasons because of the higher risk of side effects. If prescribed, the prescriber should have a well-founded indication, and the treatment should be evaluated in regular intervals. This indicator has been used in the past few years in both national and local quality indicators in Sweden for drug treatment in elderly. The following drug groups and substances are included in the definition in the 2010 version of ‘Medicines that should be avoided unless there are special reasons’: long-acting benzodiazepines, tramadol, propiomazine and medicines with anticholinergic effect (Table 1). The proportion of patients using them should be low. All mentioned medications have well-known side effects in the elderly due to age-related physiological changes. Among others, they can result in side effects such as day-fatigue, confusion or impaired balance.

Number of chronic conditions

To measure multimorbidity, we used a method developed by Calderón-Larrañaga et al at the Ageing Research Centre in Stockholm. They analysed the full list of diagnoses classified by International Classification of Diseases version 10 (ICD-10) codes on a four-digit level to define if a diagnosis is chronic or not in an elderly population. To determine if a condition is chronic or not, the following key features were identified and discussed concerning their pertinence and suitability in older populations: duration, course, reversibility, treatment and consequences. They were then grouped into 60 groups of chronic conditions. We applied their definition and list on chronic conditions to estimate the multimorbidity in the study population. Multimorbidity was then estimated by counting the number of chronic conditions in each patient. All information about diagnoses for a 2-year period (2011–2012) was obtained from the electronic medical record database from the county council in Blekinge. Diagnoses from both primary and secondary care centres were included. Five intervals were then created for the number of chronic conditions (no chronic conditions, one, two to four, five to seven, and eight or more) for the statistical analyses.

Use of medications

Information about the use of prescribed dispensed medicines was obtained from the county councils register on dispensed medicines for all inhabitants in Blekinge, which was received from the Swedish eHealth Agency. The register contains the same data on prescribed medicines as the Prescribed Drug Register at the Swedish National Board of Health and Welfare, a national register with patient level data on all dispensed prescriptions. However, the coverage is restricted to the residents in the county. The register does not contain information on use of ‘over-the-counter’ medications or illicit medication use.

In Sweden, prescribed medicines are generally prescribed for a 3-month period within the high cost threshold for medicines. Therefore, a 3-month period was used to construct a virtual medicine list on prescribed medicines. For each patient, a list of all dispensed medicines within the last 3 months was generated. This list was then matched with the list of all dispensed medicines within the same period.

Table 1 Potential inappropriate medication according to Swedish National Board of Health and Welfare’s definition 2010

| Groups                          | Substance          | ATC code     |
|---------------------------------|--------------------|--------------|
| Long-acting benzodiazepines     | Diazepam           | N05BA01      |
|                                 | Nitrazepam         | N05CD02      |
|                                 | Flunitrazepam      | N05CD03      |
| Tramadol                        | Tramadol           | N02A×02      |
| Propiomazine                    | Propiomazine       | N05CM06      |
| Drugs with anticholinergic effect | Glycopyronium bromide | A03AB02     |
|                                 | Atropine           | A03BA01      |
|                                 | Hyoscymine         | A03BA03      |
|                                 | Butyl scopolamine  | A03BB01      |
|                                 | Methyl scopolamine | A03BB03      |
|                                 | Scopolamine        | A04AD01      |
|                                 | Disopyramide       | C01BA03      |
|                                 | Oxybutynin         | G04BD04      |
|                                 | Tolterodine        | G04BD07      |
|                                 | Solifenacin        | G04BD08      |
|                                 | Darifenacin        | G04BD10      |
|                                 | Fesoterodine       | G04BD11      |
|                                 | Morphine and spasmolytic | N02AG01   |
|                                 | Ketobemidone and spasmolytic | N02AG02 |
|                                 | Trihexyphenidyl    | N04AA01      |
|                                 | Biperiden          | N04AA02      |
|                                 | Levomepromazine    | N05AA02      |
|                                 | Chlorprothixene    | N05AF03      |
|                                 | Clozapine          | N05AH02      |
|                                 | Hydroxyzine        | N05BB01      |
|                                 | Clomipramine       | N06AA04      |
|                                 | Amitriptyline      | N06AA09      |
|                                 | Nortriptyline      | N06AA10      |
|                                 | Maprotiline        | N06AA21      |
|                                 | Dimenhydrinate     | R06AA02      |
|                                 | Dextchlorpheniramine | R06AB02    |
|                                 | Chlorpheniramine   | R06AB04      |
|                                 | Alimemazine        | R06AD01      |
|                                 | Promethazine       | R06AD02      |
|                                 | Promethazine cominations | R06AD52 |
|                                 | Cyproheptadine     | R06A×02      |

ATC, anatomical therapeutic and chemical.
collected medicines. The date a case was admitted to hospital was the index date for each risk set (matched case and control). If the same drug was dispensed more than once, it was counted only once. Since the county councils register of dispensed medicines does not contain the dose text, we used defined daily dose (DDD) to calculate the duration of the drug exposure for every individual. We assumed 0.9 DDD for regularly used medicines based on calculations for regularly used medicines in an elderly population. Medicines were classified according to the anatomical therapeutic and chemical (ATC) system. From the constructed medication list, the number of medicines and use of PIM according to the stated definition was calculated on each index date. For the statistical analysis, the number of medicines was categorised into five intervals (no medication, 1 to 4, 5 to 9, 10 to 14, and 15 or more) based on definition for polypharmacy.

**Statistical analysis**

Descriptive demographic statistics and analyses were made with cross-tabulations and χ² test. A p value <0.05 was considered statistically significant. Test of trend was used to analyse use of PIM according to the number of chronic conditions and number of medications. To analyse the OR for the hospitalisation in patients, we used conditional logistic regression and we created five different models to analyse the importance of the outcome variables. Models A to C were univariate analyses for each included variable; model D adjusted for the number of chronic conditions; model E adjusted for the number of chronic conditions and number of medicines. The results are presented as OR with 95% CI. All statistical analyses were performed with STATA V.14 (Stata Corporation, Texas, USA).

**Ethical considerations**

Data in the present study are based on anonymised information provided by the County Council of Blekinge. They provided anonymised information for research purposes once the study had been vetted and approved by the Regional Ethical Review Board according to Swedish ethical review regulations. Due to the requirement of anonymised data, each individual could not be asked for consent to participate; active refusal of participation was instead applied. This was done by publishing information about the planned study in the Swedish local newspapers ‘Sydöstran’ and ‘Blekinge Läns Tidning’. The advertisement outlined the study and contained information on how to contact the data extractor in Blekinge County Council by phone, email or mail in order to opt out of the study. The data manager was then responsible for ensuring that those who opted out were excluded before any data were delivered to the research manager (first author).

**Patient and public involvement**

There was no patient or public involvement in the development or the conducting of the study. The results are being presented at a public defence as a part of a doctoral thesis.

**RESULTS**

There were 2941 patients with at least one hospitalisation to a medical, geriatric and palliative, or orthopaedic ward during 2013 and 2860 of these patients were included in the study. Of 81 cases excluded, 78 were excluded because of incomplete data and 3 because of absence of controls. In total, 5720 individuals were included and formed 2860 risk sets. There were 3314 (58%) women and 2406 (42%) men, with a mean age of 84 years. The mean age in women was 85 years, and in men, it was 83 years. In 87% of the cases, the patients were admitted to a medical ward, 13% to an orthopaedic ward and only 14 patients (0.49%) to the geriatric and palliative ward. In the descriptive analysis, age was categorised into four groups: 75–<80, 80–<85, 85–<90 and ≥90 (table 2). The χ² test shows that there is a significant difference between controls and cases in the number of chronic diagnoses and number of medicines. Use of PIM was increasing with the increase of the number of chronic conditions but not as much as with increasing the number of medicines (table 3). In the univariate analysis of hospitalisation during use of PIM, the OR was 1.54 (95% CI 1.30 to 1.83) (table 4). In the univariate analysis for the number of chronic conditions, the OR was significant from two to four chronic conditions (OR 1.27, 95% CI 1.04 to 1.56) and then continued to increase. The number of medicines has the strongest association for hospitalisation in the univariate analysis and the OR increased exponentially for each interval of the number of medicines 5 to 9 medicines (OR 1.86, 95% CI 1.55 to 2.90), 10 to 14 medicines (OR 3.10, 95% CI 2.44 to 3.93), ≥15 medicines (OR 6.93, 95% CI 4.25 to 11 to 30). When the number of chronic conditions was added to the model, the association for hospitalisation during use of PIM decreased to OR 1.39, 95% CI 1.16 to 1.66. For the number of chronic conditions, the association was significant from two to four chronic conditions (OR 1.26, 95% CI 1.03 to 1.54) and was doubled for five to seven chronic conditions (OR 2.30, 95% CI 1.86 to 2.85) and for greater than or equal to eight chronic conditions (OR 3.94, 95% CI 3.08 to 5.04). In the full model, the use of PIM was not significant. The number of chronic conditions was significant from five to seven chronic conditions (OR 1.86, 95% CI 1.49 to 2.33) and for greater than or equal to eight chronic conditions (OR 2.70, 95% CI 2.08 to 3.51). The strongest association for hospitalisation in the full model was the number of medicines. For five to nine medicines used at the same time, the OR was doubled for each interval of the number of medicines; five to nine medicines; OR 1.86 (CI 95% 1.55 to 2.90). Ten to 14 medicines, OR 3.10 (95% CI 2.44 to 3.93). Fifteen and more medicines, OR 6.93 (95% CI 4.25 to 11 to 30).

**DISCUSSION**

The number of chronic conditions and medicines had the strongest association to hospitalisation in elderly patients in this study. Use of PIM, as defined here, was
non-significant for hospitalisation in the full model with the number of chronic conditions and number of medicines. However, use of PIM was associated with increased number of chronic conditions, and to a higher degree, an increased number of medicines. The association to hospitalisation for number of chronic conditions and number of medicines was increased from five or more for both variables. The findings from this study indicate that the focus has to shift from only deprescribing of PIM to more optimisation of the medicine treatment, including care optimisation in each individual patient according to the number of chronic conditions and treatment phase (preventive, curative or palliative treatment).

Strengths and limitations
Previous studies have found that the use of PIM is a risk factor for hospitalisation.19–21 Our results show a more complex picture where the number of chronic conditions and the number of medicines have a large share. This can be due to the definition of PIM used in this study that differs from some of them in PRISCUS list, Beers’ and the STOPP criteria.22–24 Our definition from the Swedish National Board of Health and Welfare is stricter in its definition and includes fewer drugs and drug classes than the other definitions.6 For example, we do not include non-steroidal anti-inflammatory drug (NSAID) or cardiovascular drugs except for disopyramide. Our definition of PIM is commonly used in Sweden as an indicator for quality of drug treatment in elderly, both nationally and by local councils and is therefore relevant in this setting. This means that our results cannot be directly translated to other settings where the definition is wider.

The information on medicines in the study was register data from the county councils register that includes prescribed and pharmacy dispensed medicines for all

Table 2  Descriptive table of the study population

| Variables | Category | Control (%) | Case (%) | Total (%) | P value |
|-----------|----------|-------------|----------|-----------|---------|
| Age       | Total    | 2860        | 2860     | 5720      |         |
|           | 75–<80   | 738 (27.38) | 738 (27.38) | 1476 (25.80) |         |
|           | 80–<85   | 831 (29.06) | 831 (29.06) | 1662 (29.06) |         |
|           | 85–<90   | 711 (24.86) | 711 (24.86) | 1422 (24.86) |         |
|           | ≥90       | 580 (20.28) | 580 (20.28) | 1160 (20.28) |         |
| Gender    | Male     | 1657 (57.94) | 1657 (57.94) | 3314 (57.94) |         |
|           | Female   | 1203 (42.06) | 1203 (42.06) | 2406 (42.06) |         |
| Use of PIM| No use of PIM | 2618 (91.54) | 2503 (87.52) | 5121 (89.53) |         |
|           | Use of PIM | 242 (8.46) | 357 (12.48) | 599 (10.47) | 0.001   |
| Chronic conditions, n | 0 | 324 (11.33) | 195 (6.82) | 519 (9.07) |         |
|           | 1 | 408 (14.27) | 278 (9.72) | 686 (11.99) |         |
|           | 2–4 | 1285 (44.93) | 986 (34.48) | 2271 (39.70) |         |
|           | 5–7 | 619 (21.64) | 865 (30.24) | 1484 (25.94) |         |
|           | ≥8 | 224 (7.83) | 536 (18.74) | 760 (13.29) | 0.001   |
| Medicines, n | 0 | 422 (14.76) | 290 (10.14) | 712 (12.45) |         |
|           | 1–4 | 1348 (47.13) | 917 (32.06) | 2265 (39.60) |         |
|           | 5–9 | 896 (31.33) | 1157 (40.45) | 2053 (35.89) |         |
|           | 10–14 | 172 (6.01) | 390 (13.64) | 562 (9.83) |         |
|           | ≥15 | 22 (0.77) | 106 (3.71) | 128 (2.24) | 0.001   |

PIM, potential inappropriate medicine.

Table 3  Descriptive analyses of the use of potentially inappropriate medicine, number of chronic conditions and number of medicines.

| Variables | Total number | Use of PIM (%) | P for trend |
|-----------|--------------|----------------|-------------|
| Chronic conditions, n | 519 | 34 (6.55) | <0.001 |
|           | 686 | 63 (9.18) |            |
|           | 2271 | 196 (8.63) |            |
|           | 1484 | 185 (12.47) |            |
|           | 760 | 121 (15.92) | <0.001 |
| Drugs, n | 712 | 0 (0) |            |
|           | 2265 | 130 (5.74) |            |
|           | 2053 | 266 (12.96) |            |
|           | 562 | 151 (26.87) |            |
|           | 128 | 52 (40.63) | <0.001 |

PIM, potential inappropriate medicine.
Table 4 OR of hospitalisation, model A to C, are univariate analyses, model D includes PIM and number of chronic conditions and model E includes PIM, number of chronic conditions and number of medicines

| Variables          | Model A (OR (95% CI)) | Model B (OR (95% CI)) | Model C (OR (95% CI)) | Model D (OR (95% CI)) | Model E (OR (95% CI)) |
|--------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| No use of PIM      | 1                     | 1                     | 1                     | 1                     | 1                     |
| Use of PIM         | 1.54 (1.30 to 1.83)*   | 1.39 (1.16 to 1.66)*   | 1.09 (0.90 to 1.33)   |                       |                       |
| Chronic conditions, n |                       |                       |                       |                       |                       |
| 0                  | 1                     | 1                     | 1                     | 1                     | 1                     |
| 1                  | 1.12 (0.88 to 1.42)    | 1.11 (0.88 to 1.41)    | 1.09 (0.86 to 1.39)   |                       |                       |
| 2–4                | 1.27 (1.04 to 1.56)*   | 1.26 (1.03 to 1.54)*   | 1.15 (0.93 to 1.41)   |                       |                       |
| 5–7                | 2.35 (1.90 to 2.90)*   | 2.30 (1.86 to 2.85)*   | 1.86 (1.49 to 2.33)*  |                       |                       |
| ≥8                 | 4.06 (3.18 to 5.19)*   | 3.94 (3.08 to 5.04)*   | 2.70 (2.08 to 3.51)*  |                       |                       |
| Medicines, n       |                       |                       |                       |                       |                       |
| 0                  | 1                     | 1                     | 1                     | 1                     | 1                     |
| 1–4                | 0.99 (0.82 to 1.18)    | 0.89 (0.74 to 1.08)    |                       |                       |                       |
| 5–9                | 1.86 (1.55 to 2.22)*   | 1.46 (1.21 to 1.77)*   |                       |                       |                       |
| 10–14              | 3.10 (2.44 to 3.93)*   | 2.05 (1.59 to 2.66)*   |                       |                       |                       |
| ≥15                | 6.93 (4.25 to 11.30)*  | 3.84 (2.30 to 6.44)*   |                       |                       |                       |

*Significant.
PIM, potential inappropriate medicine.

the inhabitants in Blekinge. We were not able to assess the use of illegal drugs or over-the-counter drugs in this study. Data from the Medical Products Agency indicate that 11% of the Swedish population bought prescription drugs from non-approved pharmacies during 2011. By constructing a medicine list on collected prescribed drugs from the index date of hospitalisation and 3 months back for each risk set, it has allowed us to determine as close as possible to what the patient was likely to be using. On the other hand, there is a possibility that we are missing medications used as needed because they are collected more rarely than every 3 months. We were also unable to take compliance into consideration when determining use of PIM.

Multimorbidity in the study population was measured by the number of chronic conditions and is dependent on the quality of registration of the diagnoses. The recording of diagnoses in this study has not been validated. During 2013, Blekinge did not use any multimorbidity measurement method for reimbursement in healthcare, and therefore, the risk of up-coding in diagnoses is low. It is more likely that there was an under-registration. We used registered diagnoses from a 2-year period and from both primary and secondary care centres to get as close to total coverage as possible. Another Swedish study has found that 75% of the total population in Blekinge County had at least one diagnosis registered during a 3-year period in primary care. The time gap between the collection of diagnoses (2011–2012) and when the index date accrues for each risk set (2013) means there is a risk for underestimating the number of chronic conditions. For example, if a risk set had index date in the last 2 months of 2013, there is almost a year gap between the index date and the date of collection of diagnoses.

Other multimorbidity estimates are constructed by giving different diagnoses a weight to how much the diagnosis contributed to need of care or cost. In our definition of chronic conditions, all diagnoses contribute the same to the morbidity burden and are more an expression of the complexity of care in the patient than need of care.

The cases in this study had a higher prevalence of number of chronic conditions and number of medications than the controls. Therefore, we cannot exclude the presence of selection bias in our study. Confounding by indication may be present in our study, although we only include use of PIM, number of medicines and number of chronic conditions. Number of medications can be a confounder for specific medications that cause hospitalisation. They can also cover the effect by PIM since PIM is included in number of medications.

There is also an interaction between number of chronic conditions and use of medications. With the increase of number of chronic conditions in a patient come further increase in medication use. The risk that one of these medications is then a PIM increases. This can lead to overestimating the effect of the number of medications on the outcome.

This study does not include information on the patient’s socioeconomic status. Socioeconomic factors such as educational level or income level are known risk factors for morbidity and increased use of medication.
A low educational level is often related to an increased use of medications and inappropriate drug use also in the elderly.28–29 The absence of adjustment for educational level or income level in this study is a limitation.

Blekinge County is a small county in Sweden both in terms of population and area and has a relatively simply organised healthcare service, which makes it easy to include data from primary care, both public and private, and secondary care centres. Our results are applicable to elderly populations in similar settings.

**Implications for clinical practice**

Our results are interesting since other studies have shown that use of PIM increases the risk for hospitalisation.19–21 However, our results indicate that number of medications and number of chronic conditions are better predictors for hospitalisations in elderly than the use of PIM. With increasing number of medicines and, to a lesser degree, the number of chronic conditions, the chance of having a PIM prescribed or a drug–drug interaction increases and is a known risk factor for ADEs and DRP.5 30 31 And with increasing age and multimorbidity, the prevalence of polypharmacy increases.5 The risk–benefit ratio for treatment becomes more complex to evaluate, and physiological changes that affect pharmacokinetics and pharmacodynamics can appear fast in an elderly patient.32 The result of increasing risk of hospitalisation with increasing number of medicines and chronic conditions is confirmation of this.

Previous studies have also shown that patients with chronic diseases and with low continuity of care use more out-of-hours primary care than other patients.33 34 Causes for polypharmacy and inappropriate prescribing are many, for example, number of prescribers, communication failures and knowledge gaps at the prescriber level about the patient or the medication.10,35 For number of medications, polypharmacy can cover many other risk factors, such as underuse or overuse and inappropriate prescribing in elderly according to Kuijpers et al.36 They showed that patients with polypharmacy (defined as using four or more medications) were undertreated compared with those receiving fewer medicines (13.5%). The theory is that fear of causing ADEs is contributing to underprescribing by prescribers in patients with polypharmacy.32

The most common drugs causing ADEs are drugs that have well-documented positive effects on reducing risk of morbidity and mortality in elderly. The most common drugs causing ADEs are antiplatelet, anticoagulants, diuretics, NSAIDs, antidepressants and antibacterial preparations for systemic use.37 38 This is not surprising as all mentioned drugs are potent with a good effect in preventing morbidity when used with the right patient, at the right time and at the right dosage. However, when used inappropriately, they can cause ADEs, especially in the elderly due to their frailty.3 12 The majority of these drugs are not included in the definition of PIM used here. Together with our results, this indicates that deprescribing PIM in the elderly has to be supplemented with systematic methods for evaluating the whole medical treatment in the individual to reduce the risk for hospitalisation.

New approaches are needed to improve quality of drug treatment in the elderly and possibly coordination with other care interventions. Our results indicate that the healthcare system needs to improve the care of patients with multimorbidity, polypharmacy and use of PIM. The term appropriate polypharmacy needs to be embraced and in clinical practice it is defined as evidence-based prescribing and medicine optimisation. What it means is that when choosing treatment, the dosages are adjusted to the patient’s physiological conditions.32

However, only using number of medicines as an indicator for the assessment of drug-related problems has been shown to have limited value in clinical practice.4 When combining number of medications, number of chronic morbidities and use of medications with high risk of ADE, the clinical advantage increases. Different methods have been tested to improve drug treatment in elderly. Implementing the STOPP criteria in a hospital setting reduced the number of ADE in a study from Cork University Hospital.39 The STOPP criteria are wider in its definition for PIM than in this study. The STOPP criteria are a collection of indicators to detect and stop potentially inappropriate prescribing. The complete collection of quality criteria in “Quality indicators for good drug therapy in elderly” can be used in the same way.9 However, evaluating the effect is more complex than measuring the use of PIM when evaluating quality of care in the elderly on a population level. There are several studies showing that using a systematic method, such as medication review, in multiprofessional teams reduces the prevalence of potentially inappropriate prescribing, the use of PIM and medication cost. It is a method developed not to focus on specific risk medication but a systematic approach to optimise a patient’s medical treatment as a whole; diagnoses, medicines and patient’s physical conditions, for example, kidney function.40–42 The method is more complex to evaluate on a population level, but the clinical effect is greater.

When developing new indicators for evaluating quality of medication use in elderly, our results strongly indicate that focus should shift from only deprescribing PIM to include total medicine optimisation for each individual.

**Future research**

There are many studies done on the topic of pharmaceutical care in elderly.40 41 43 A new structure needs to be established around the elderly with multimorbidity and/or polypharmacy to improve the pharmacology care. Polypharmacy is a large risk factor for ADE and hospitalisations. However, to find patients in need for a medical review before an ADE, multimorbidity also needs to be considered. More focus needs to be on the appropriate drug treatment in relation to the individual patient, instead of potentially inappropriate treatment in general.
Future healthcare systems need to step up the care for the elderly to be able to handle the challenges of a complex drug treatment in a patient with multimorbidity. Future research needs to investigate different models to manage the complexity that surrounds the elderly patient. For example, analysing multiple interventions that one-by-one have little impact on the risk but together can increase the quality of drug treatment.

CONCLUSION
The number of medications and the number of chronic conditions are strong risk factors for hospitalisation. PIMs (defined as long-acting benzodiazepines, medications with anticholinergic effect, tramadol and propiomazine) do not have an increased OR for hospitalisation in relation to the number of chronic conditions and number of medications. This study confirms what previous studies have found, that there are multiple causes to ADEs and drug-related hospitalisations. Focus must shift from only deprescribing PIM to evidence-based prescribing and medicine optimisation in patients with use of PIM, polypharmacy and high multimorbidity. The healthcare structure needs to support implementation of methods that facilitate follow-up of drug treatments in the elderly more frequently and gives the healthcare personnel the right conditions.

Acknowledgements We are indebted to Patrick Reilly for his expertise and invaluable advice in proofreading the manuscript. We are indebted to Karin Ranstad for her support and invaluable advice in completing the manuscript.

Contributors In accordance with the Vancouver Protocol, KT, AH, PM and JF all have contributed to the design of this study. KT, AH and JF researched data and conducted the statistics. KT, AH and PM wrote the manuscript.

Funding This work was funded by Blekinge county council’s research council.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval The Regional Ethical Review Board at Lund University (application 2015/712) approved the study.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data may be obtained from a third party and are not publicly available.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Kristine Thorell http://orcid.org/0000-0002-4831-3888
Patrik Midlöv http://orcid.org/0000-0002-5871-8731

REFERENCES
1. Shi S, Mörkne K, Klotz U. The clinical implications of ageing for rational drug therapy. Eur J Clin Pharmacol 2008;64:183–99.
2. Thorell K, Skoog J, Zielinski A, et al. Licit prescription drug use in a Swedish population according to age, gender and socioeconomic status after adjusting for level of multi-morbidity. BMC Public Health 2012;12:575.
3. Calderón-Lrañaga A, Vetrano DL, Onder G, et al. Assessing and measuring chronic multimorbidity in the older population: a proposal for its Operationalization. J Gerontol A Biol Sci Med Sci 2017;72:1417–23.
4. Vikti KK, Blix HS, Moger TA, et al. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. Br J Clin Pharmacol 2007;63:187–95.
5. Davies EA, O’Mahony MS. Adverse drug reactions in special populations - the elderly. Br J Clin Pharmacol 2015;80:796–807.
6. Swedish National Board of Health and Welfare. Indikator for god läkemedelsstöd hos äldre, 2010. Available: https://www.socialstyrelsen.se/publikation2010/2010-6-29 [Accessed Dec 2018].
7. Mjördal T, Boman MD, Hägg S, et al. Adverse drug reactions as a cause for admissions to a department of internal medicine. Pharmacoepidemiol Drug Saf 2002;11:65–72.
8. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004;329:15–19.
9. Wintervestein AG, Sauer BC, Hepler CD, et al. Preventable drug-related hospital admissions. Ann Pharmacother 2006;36:1238–48.
10. Howard R, Avery A, Bissell P. Causes of preventable drug-related hospital admissions: a qualitative study. Qual Saf Health Care 2008;17:109–16.
11. Paul E, End-Rodrigues T, Thylen P, et al. [Adverse drug reactions a common cause of hospitalization of the elderly. A clinical retrospective study]. Lakartidningen 2008;105:2338–42.
12. Odar-Cederløf I, Oskarsson P, Ohlén G, et al. [Adverse drug effect as cause of hospital admission. Common drugs are the major part according to the cross-sectional study]. Lakartidningen 2008;105:890–3.
13. Campanelli CM, American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American geriatrics Society updated bees criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2009;57:165–8.
14. Hamilton H, Gallagher P, Ryan C, et al. Potentially inappropriate medications defined by STOPP criteria and the risk of adverse drug events in older hospitalized patients. Arch Intern Med 2011;171:1013–9.
15. Wettermark B, Hammar N, Fored CM, et al. The new Swedish prescribed drug Register—Opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007;16:726–35.
16. Johnell K, Fastbom J. The use of benzodiazepines and related drugs amongst older people in Sweden: associated factors and concomitant use of other psychotropics. Int J Geriatr Psychiatry 2009;24:731–8.
17. World Health Organization. WHO collaborating center for drug statistics methodology Oslo, 2018. Available: https://www.whocc.no/ [Accessed 15 Nov 2018].
18. STATA statistics software, 2019. Available: https://www.stata.com/ [Accessed 27 may 2019].
19. Varga S, Alcusky M, Keith SW, et al. Hospitalization rates during potentially inappropriate medication use in a large population-based cohort of older adults. Br J Clin Pharmacol 2017;83:2572–90.
20. Sköldunger A, Fastbom J, Wimo A, et al. Impact of inappropriate drug use on hospitalizations, mortality, and costs in older persons and persons with dementia: findings from the SnAC study. Drugs Aging 2015;32:213–8.
21. Endres HG, Kaufmann-Kolle P, Steeb V, et al. Association between potentially inappropriate medication (PIM) use and risk of hospitalization in older adults: an observational study based on routine data comparing PIM use with use of Pim alternatives. PLoS One 2016;11:e0164401.
22. Holt S, Schmiell S, Thürmann PA. Potentially inappropriate medications in the elderly: the PRISCUS list. Dtsch Arztebl Int 2010;107:543–51.
23. By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2015;63:2227–46.
24. O’Mahoney D, O’Sullivan D, Byrne S, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing 2014;44:213–8.
25. Medical Products Agency. Läkemedelsverket arbete för att motverka olagliga läkemedel, 2011. Available: http://www. läkemedelsverket.se/upload/nyheter/2012/Regeringsuppdrag% 20olaga%20lakemedel%202011-12-30.pdf [Accessed 24 Jan 2019].
26. Carlsson L, Strender L-E, Frith G, et al. Clinical categories of patients and encounter rates in primary health care – a three-year study in defined populations. BMC Public Health 2006;6:35.
27. Starfield B, Weiner J, Mumford L, et al. Ambulatory care groups: a categorization of diagnoses for research and management. Health Serv Res 1991;26:53–74.

28. Haider SI, Johnell K, Ringbäck Weitoft G, et al. Patient educational level and use of newly marketed drugs: a register-based study of over 600,000 older people. Eur J Clin Pharmacol 2008;64:1215–22.

29. Haider SI, Johnell K, Weitoft GR, et al. The influence of educational level on polypharmacy and inappropriate drug use: a register-based study of more than 600,000 older people. J Am Geriatr Soc 2009;57:82–9.

30. Parameswaran Nair N, Chalmers L, Bereznicki BJ, et al. Repeat adverse drug Reaction-Related hospital admissions in elderly Australians: a retrospective study at the Royal Hobart Hospital. Drugs Aging 2017;34:777–83.

31. Wimmer BC, Bell JS, Fastbom J, et al. Medication regimen complexity and number of medications as factors associated with unplanned hospitalizations in older people: a population-based cohort study. J Gerontol A Biol Sci Med Sci 2016;71:831–7.

32. Cadogan CA, Ryan C, Hughes CM, et al. Appropriate polypharmacy and medicine safety: when many is not too many. Drug Saf 2016;39:109–16.

33. Kohnke H, Zielinski A. Association between continuity of care in Swedish primary care and emergency services utilisation: a population-based cross-sectional study. Scand J Prim Health Care 2017;35:113–9.

34. Flarup L, Moth G, Christensen MB, et al. Chronic-disease patients and their use of out-of-hours primary health care: a cross-sectional study. BMC Fam Pract 2014;15:114.

35. Green JL, Hawley JN, Rask KJ. Is the number of prescribing physicians an independent risk factor for adverse drug events in an elderly outpatient population? Am J Geriatr Pharmacother 2007;5:31–9.

36. Kuipers MAJ, van Marum RJ, Egberts ACG, et al. Relationship between polypharmacy and underprescribing. Br J Clin Pharmacol 2008;65:130–3.

37. Swedish National Board of Health and Welfare. Läkemedelorskad sjuklighet hos äldre, 2014. Available: http://www.socialstyrelsen.se/publikationer2014/2014-12-13 [Accessed May 2018].

38. Howard RL, Avery AJ, Slavenburg S, et al. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol 2007;63:136–47.

39. O’Connor MN, O’Sullivan D, Gallagher PF, et al. Prevention of hospital-acquired adverse drug reactions in older people using screening tool of older persons' prescriptions and screening tool to alert to right treatment criteria: a cluster randomized controlled trial. J Am Geriatr Soc 2016;64:1558–66.

40. Milos V, Rekman E, Bondesson Åsa, et al. Improving the quality of pharmacotherapy in elderly primary care patients through medication reviews: a randomised controlled study. Drugs Aging 2013;30:235–46.

41. Lenander C, Bondesson Åsa, Viberg N, et al. Effects of medication reviews on use of potentially inappropriate medications in elderly patients; a cross-sectional study in Swedish primary care. BMC Health Serv Res 2018;18:616.

42. Gillespie U, Alassaad A, Henrohn D, et al. A comprehensive pharmacist intervention to reduce morbidity in patients 80 years or older. Arch Intern Med 2009;169:894–900.

43. Chau SH, Jansen APD, van de Ven PM, et al. Clinical medication reviews in elderly patients with polypharmacy: a cross-sectional study on drug-related problems in the Netherlands. Int J Clin Pharm 2016;38:46–53.